What drives the volume spike in GV.PA stock pre-market?

The spike is driven by speculative order flow and low free float relative to trade interest. GV.PA’s pre-market **38.49M** volume far exceeds average **14.22M**, indicating short-term liquidity rather than a sustained fundamental shift.

How does Meyka AI view GV.PA stock performance?

Meyka AI assigns GV.PA a score of **62.60** (Grade B, HOLD) based on benchmarks, sector metrics, growth and forecasts. The grade highlights active trading but weak fundamentals and liquidity risks.

What price targets and upside are realistic for GV.PA stock?

Scenario targets: conservative **€0.0015**, base **€0.0030**, optimistic **€0.0100**. Meyka AI’s model projects **€0.0060** in 12 months, implying **+233.33%** vs **€0.0018**, but forecasts are not guarantees.

Should investors hold GV.PA stock amid high volatility?

Given EPS **-0.11**, tight liquidity metrics and potential dilution, risk-tolerant traders may enter short-term. Long-term investors should wait for consistent revenue growth or improved cash flow before adding to portfolios.

EU Stocks

GV.PA Genomic Vision (EURONEXT) pre-market €0.002 14 Mar 2026: 38.49M shares most active

ByDanny Kontos March 14, 2026March 14, 2026

GV.PA stock is the pre-market standout on EURONEXT on 14 Mar 2026, trading at €0.0018 with 38.49M shares in early activity. The tiny market cap of €693,191 and extreme volume spike (relative volume 2.71x) flag short-term liquidity and speculative trading rather than fundamental repositioning. Investors should weigh the unusual turnover against negative earnings (EPS -0.11) and stretched valuation metrics before positioning for a bounce.